XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients (GlobeNewswire via Yahoo! Finance)
February 9th, 2010
BERKELEY, Calif. — XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody candidate, XOMA 052, in Type 2 diabetes patients.
Original post by macular degeneration – Google News
(click on the author/publication link above to see full post)